The global fight against HIV, tuberculosis and malaria is set for a leadership change following the appointment of Dr Mark Dybul as the next Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria.
The Global Fund Board announced the appointment on October 28, 2026, confirming that Dybul will begin a four-year term in early 2027. He will succeed Peter Sands, who has led the organisation since 2018.
The appointment brings back a familiar figure to the international health organization. Dybul previously served as Executive Director of the Global Fund between 2013 and 2017, giving him experience in managing one of the world’s largest financing partnerships for infectious disease control.
A medical doctor and professor of medicine at Georgetown University, Dybul has spent more than 25 years working in HIV prevention, treatment and global health policy. He also played an important role in developing the United States President’s Emergency Plan for AIDS Relief (PEPFAR), which supports HIV prevention and treatment programmes worldwide.
Global Fund Faces Funding Challenges in Fight Against Three Diseases
Dybul’s appointment comes at a challenging period for international health financing. The Global Fund is facing pressure to sustain programmes that provide HIV treatment, tuberculosis care and malaria prevention across countries with significant disease burdens.
Its eighth replenishment campaign, which concluded in November 2025, raised US$12.64 billion against a target of US$18 billion. This left a shortfall of US$5.36 billion, raising concerns about the resources available to maintain and expand disease-control programmes.
The funding partnership plays a major role in supporting access to antiretroviral therapy for people living with HIV, tuberculosis diagnosis and treatment, insecticide-treated mosquito nets and other malaria prevention measures.
According to the organisation’s 2026 results report, programmes supported by the Global Fund had saved 72 million lives since its establishment in 2002. In 2025, approximately 26.9 million people were receiving antiretroviral therapy in countries where the partnership invests.
These interventions also support healthcare workers, laboratories, community health services and essential medical supplies, making the organisation an important contributor to health system development, particularly in low- and middle-income countries.
Dybul’s return is therefore significant for countries that depend on international health funding to sustain HIV, tuberculosis and malaria programmes. His experience with PEPFAR and previous leadership of the Global Fund could shape the organisation’s approach to partnerships, financing and disease prevention. Meanwhile, Peter Sands will continue overseeing the organisation until Dybul officially assumes the position in early 2027.
The incoming Executive Director is expected to lead the partnership through changing global health financing conditions while maintaining efforts to reduce deaths from the three major infectious diseases.
The transition will be closely watched by governments, healthcare organizations and communities that rely on the Global Fund’s support for essential treatment and prevention services.
English